Bonguard Naturals' Nixodine-S™ Study Suggests Potential Nicotine Alternative
Bonguard Naturals announced results from a preclinical study of its Nixodine-S™ compound. The compound appears to preserve nicotine-like activity while demonstrating more favorable cytotoxicity results.
Bonguard Naturals has announced the results of a preclinical study concerning its patented Nixodine-S™ compound. According to the study, Nixodine-S™ preserves activity at key satisfaction-related receptors, mimicking nicotine's effects.
A significant finding from the research is that Nixodine-S™ exhibited markedly more favorable in vitro cytotoxicity results compared to nicotine under the tested conditions. This suggests the compound could offer the stimulating and satisfying aspects of nicotine without its known cellular toxicity.
The company released these findings on August 24, 2026. While preliminary, the results indicate a potential pathway for developing products that could deliver a nicotine-like experience with a potentially improved safety profile. Further details on the study's methodology and specific outcomes have not yet been disclosed.
This development could represent a notable advancement in the market for smoking cessation aids or nicotine-free alternatives. Bonguard Naturals' patented compound is currently in the preclinical phase, and its future development will necessitate further research and regulatory approvals.